New Data at ESC Congress 2026 Validate Caristo's FAI-Score™ Biomarker and Highlight Potential Non-Contrast Cardiac CT Opportunity
PR Newswire
MUNICH, Aug. 31, 2026
—Independent Oxford-led data showcase the value of coronary inflammation assessment in non-contrast cardiac CT, identifying risk even in patients with zero coronary calcium——Late-breaking ORFAN-MAESTRIA data and additional investigator-led analyses highlight broader scientific applications of Caristo's AI platform in future stroke risk prediction—MUNICH, Aug. 31, 2026 /PRNewswire/ -- Caristo Diagnostics, a global leader in AI technologies for cardiovascular disease, today announced new independent University of Oxford-led research presented at the European Society of Cardiology (ESC) Congress 2026 showing that Caristo's FAI-Score™ biomarker can unlock coronary inflammation assessment in non-contrast cardiac CT, identifying high risk even in patients with a zero coronary calcium score.1 The findings build on the same coronary inflammation biology and AI technology underpinning the CaRi-Heart® technology, Caristo's FDA-authorized and first and only commercially available product for coronary inflammation assessment from routine coronary CT angiography.
